Stocks
Stocks
Last updated: June 7, 2026
Becton, Dickinson and Company offers strong revenue and a low beta, indicating stability, but with a higher PE ratio, it may be pricier relative to earnings. ONEOK, Inc. presents a compelling dividend yield and lower valuation metrics, making it attractive for income-focused investors. This comparison reveals distinct value propositions tailored to different investment goals.
| Aspect | Becton, Dickinson and Company | ONEOK, Inc. | Winner |
|---|---|---|---|
| Market Capitalization | $41.65 billion | $55.60 billion | ONEOK, Inc. |
| PE Ratio | 26.38 | 15.73 | ONEOK, Inc. |
| Dividend Yield | 2.78% | 4.85% | ONEOK, Inc. |
| Price to Earnings (EPS) | EPS of 5.73 | EPS of 5.61 | Tie |
| Beta (Market Volatility) | 0.278 | 0.714 | Becton, Dickinson and Company |
Market Capitalization: ONEOK's larger market cap indicates more extensive market valuation and possibly more stability in its stock price compared to Becton, Dickinson, which has a market cap of approximately $41.65 billion.
PE Ratio: ONEOK's significantly lower PE ratio of 15.73 suggests a more attractive valuation relative to earnings, especially for value investors seeking stock undervaluation.
Dividend Yield: ONEOK offers a notably higher dividend yield, making it more appealing for income-focused investors looking for steady cash flow from their investments.
Price to Earnings (EPS): Both companies have similar earnings per share, with Becton, Dickinson slightly ahead, indicating comparable profitability at the current valuation.
Beta (Market Volatility): Becton, Dickinson's low beta of 0.278 points to less market volatility and a more stable stock during economic fluctuations, ideal for conservative investors.
Becton, Dickinson and Company (BDX), operating within the healthcare sector and specializing in medical instruments and supplies, boasts a revenue of approximately $22.2 billion and a market capitalization around $41.65 billion. Its PE ratio of 26.38 reflects a premium valuation, likely due to its stable profit margins and growth prospects in medical devices. Notably, BDX's beta of 0.278 indicates very low volatility, making it suitable for risk-averse investors seeking steady returns. Its dividend yield of 2.78% adds additional value, especially for income-focused portfolios.
In contrast, ONEOK, Inc. is part of the energy sector with a focus on oil and gas midstream operations. It reports a higher revenue of $35.2 billion and a larger market cap of approximately $55.60 billion, signaling broader market confidence and scale. Its PE ratio of 15.73 suggests it is valued more attractively relative to earnings, appealing to value investors. Furthermore, ONEOK offers a dividend yield of 4.85%, almost double that of Becton, Dickinson, making it more attractive for those prioritizing dividend income.
When analyzing profitability, both companies have similar EPS figures (BDX at 5.73 and OKE at 5.61), indicating comparable earnings efficiency. However, ONEOK's higher profit margin of 10.03% versus BDX's 5.12% points to superior operational efficiency in the energy sector. The sector-specific risks and growth prospects differ significantly: healthcare stocks like BDX tend to be more stable with steady growth, whereas energy stocks such as ONEOK can be more volatile but offer higher income through dividends.
In terms of valuation metrics, ONEOK's lower PE ratio and higher dividend yield give it a clear advantage for value and income investors. Conversely, Becton, Dickinson's very low beta and stable revenue profile may appeal to conservative investors seeking less market fluctuation. Both stocks present compelling value propositions, but for risk-averse investors prioritizing stability and income, ONEOK offers a better value-for-money deal. Meanwhile, those willing to accept slightly higher valuation multiples for stability might prefer BDX.
ONEOK, Inc. emerges as the better value-for-money stock for income-focused and value investors due to its lower PE ratio of 15.73, higher dividend yield of 4.85%, and larger market cap, indicating broader market confidence. Becton, Dickinson offers stability with a low beta of 0.278 and a solid revenue base but at a higher valuation. Therefore, for investors seeking higher income and attractive valuation metrics, ONEOK provides a more compelling value proposition, while BDX remains preferable for those prioritizing stability and healthcare sector exposure.
Investors seeking stability in healthcare stocks, those prioritizing low volatility, and dividend income from the medical devices industry.
Income-focused investors, value investors, and those seeking exposure to the energy sector with higher dividend yields and lower valuation multiples.